MLTX

MoonLake Immunotherapeutics

NASDAQ: MLTX · HEALTHCARE · BIOTECHNOLOGY

$18.39

+2.24% today

Updated 2026-06-03

Market cap

$1.41B

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-3.88

Dividend yield

—

52W range

$6 – $63

Volume

1.0M

Market cap

$1.41B

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-3.88

Dividend yield

—

52W range

$6 – $63

Volume

1.0M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.3

Growth

5.5

Quality

C+

3.0

Profitability

5.0

Valuation

C+

1/9

Piotroski F-Score

Weak

-0.7

Altman Z-Score

Distress

—

Industry rank

—

View all highly rated stocks (75+) →205 stocks currently score above 75

Price targets

Analyst target

$27.62

+50.19%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

1 Strong Buy10 Buy2 Hold2 Sell0 Strong Sell

Price chart

Stock snapshot

Strengths

+ Debt/equity 0.40x — low leverage

Risks

- Piotroski 1/9 — weak financial health

- Altman Z -0.67 — distress zone

- Thin margins at 0.00%

- Negative free cash flow $-66.29M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Net income	$-64.51M	$-36.01M	$-118.94M	$-227.32M	$-69.71M
EPS	—	—	—	—	$-3.88
Free cash flow	$-55.91M	$-43.06M	$-117.11M	$-196.04M	$-66.29M
Profit margin	—	—	—	—	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
MLTX	$1.41B	23	4.3	3.0	5.0	5.5	—	Avoid
LLY	$1.08T	78	10.0	10.0	5.0	6.0	—	Strong Buy
JNJ	$613.02B	57	4.7	9.0	3.3	6.0	-87.08%	Buy
ABBV	$447.62B	63	4.0	8.0	4.7	5.0	-73.27%	Buy
UNH	$388.59B	54	5.3	5.5	4.0	5.5	-33.19%	Buy
NVS	$296.54B	49	3.3	9.0	3.3	4.5	-69.70%	Hold

Smart narrative

MoonLake Immunotherapeutics trades at $18.39. Our Smart Value Score of 23/100 indicates the stock is weak. The company scores 1/9 on the Piotroski F-Score. With an Altman Z-Score of -0.67, it sits in the distress.

Frequently asked questions

What is MoonLake Immunotherapeutics's stock price?

MoonLake Immunotherapeutics (MLTX) trades at $18.39.

Is MoonLake Immunotherapeutics overvalued?

MoonLake Immunotherapeutics carries a Smart Value Score of 23/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.

What is the price target of MoonLake Immunotherapeutics (MLTX)?

The 12-month analyst consensus target is $27.62, about 50.2% above the current $18.39. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.

Altman Z-Score?

MoonLake Immunotherapeutics's Altman Z-Score is -0.67, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio—

ROE-77.80%

Beta1.04

50D MA$17.89

200D MA$18.82

Shares out0.07B

Float0.04B

Short ratio—

Avg volume1.0M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

MLTX vs LLY →MLTX vs JNJ →MLTX vs ABBV →Stock screener →